Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > What's The Chance !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(97)
•••
Comment by WORKINMONTANAon Aug 30, 2021 7:35pm
120 Views
Post# 33785947

RE:What's The Chance !!!

RE:What's The Chance !!!Which one?

St Biosciences 
SYNCA Labs AG
The Bracken Group
ST Therapeutics 




HighSkies2019 wrote: Any chance the next nr or halt is re a buyout .... all the excited posts leading up to rs about the great nr to follow right after rs ....sure has given us nothing but a kick in the gut ....the halt on Aug 18th didn't make sense to me for the nr we got...on July 19 I posted about financials our next nr because I felt something seems to keep this being delayed .... today seeing that our financials seem to be more important then giving us something solid....now makes me tell you this ... check out Andrew Salzman new update on LinkedIn and see credentials and a team member on another company Aug 2021....no mention on connection to Claritas as it was there before...I dunno know boys and girls ....what do you think....glta


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities